Some are saying that this is the reason for the egg shortage, which wouldn’t surprise me. There is another theory that they are shutting down the facilities that are putting plastic into eggs (yes – I guess they are really doing this.) Article below:
- PMID: 33191178
- PMCID: PMC7608017
- DOI: 10.1016/j.intimp.2020.107172
Abstract
The SARS-CoV-2 virus is still spreading worldwide, and there is an urgent need to effectively prevent and control this pandemic. This study evaluated the potential efficacy of Egg Yolk Antibodies (IgY) as a neutralizing agent against the SARS-CoV-2. We investigated the neutralizing effect of anti-spike-S1 IgYs on the SARS-CoV-2 pseudovirus, as well as its inhibitory effect on the binding of the coronavirus spike protein mutants to human ACE2. Our results show that the anti-Spike-S1 IgYs showed significant neutralizing potency against SARS-CoV-2 pseudovirus, various spike protein mutants, and even SARS-CoV in vitro. It might be a feasible tool for the prevention and control of ongoing COVID-19.
Keywords: Chicken Egg Yolk Antibodies; IgY; Neutralizing agent; SARS-CoV-2; Spike protein variants.
Copyright © 2020 Elsevier B.V. All rights reserved.
Figures
Similar articles
-
Immunoglobulin yolk targeting spike 1, receptor binding domain of spike glycoprotein and nucleocapsid of SARS-CoV-2 blocking RBD-ACE2 binding interaction.Int Immunopharmacol. 2022 Nov;112:109280. doi: 10.1016/j.intimp.2022.109280. Epub 2022 Sep 28.PMID: 36183680 Free PMC article.
-
Mutations in spike protein and allele variations in ACE2 impact targeted therapy strategies against SARS-CoV-2.Zool Res. 2021 Mar 18;42(2):170-181. doi: 10.24272/j.issn.2095-8137.2020.301.PMID: 33738989 Free PMC article.
-
Novel human neutralizing mAbs specific for Spike-RBD of SARS-CoV-2.Sci Rep. 2021 May 26;11(1):11046. doi: 10.1038/s41598-021-90348-7.PMID: 34040046 Free PMC article.
-
Egg yolk immunoglobulin (IgY) targeting SARS-CoV-2 S1 as potential virus entry blocker.J Appl Microbiol. 2022 Mar;132(3):2421-2430. doi: 10.1111/jam.15340. Epub 2021 Nov 3.PMID: 34706134 Free PMC article.
-
Possible inhibition of GM-CSF production by SARS-CoV-2 spike-based vaccines.Mol Med. 2021 May 22;27(1):49. doi: 10.1186/s10020-021-00313-3.PMID: 34022793 Free PMC article.
Cited by
-
SARS-CoV-2-specific immunoglobulin Y antibodies are protective in infected mice.PLoS Pathog. 2022 Sep 19;18(9):e1010782. doi: 10.1371/journal.ppat.1010782. eCollection 2022 Sep.PMID: 36121829 Free PMC article.
-
Development of a Monoclonal scFv against Cytotoxin to Neutralize Cytolytic Activity Induced by Naja atra Venom on Myoblast C2C12 Cells.Toxins (Basel). 2022 Jul 4;14(7):459. doi: 10.3390/toxins14070459.PMID: 35878197 Free PMC article.
-
Application of Baculovirus Expression Vector system (BEV) for COVID-19 diagnostics and therapeutics: a review.J Genet Eng Biotechnol. 2022 Jul 6;20(1):98. doi: 10.1186/s43141-022-00368-7.PMID: 35792966 Free PMC article. Review.
-
A unique antigen against SARS-CoV-2, Acinetobacter baumannii, and Pseudomonas aeruginosa.Sci Rep. 2022 Jun 27;12(1):10852. doi: 10.1038/s41598-022-14877-5.PMID: 35760825 Free PMC article.
-
Egg-Derived Anti-SARS-CoV-2 Immunoglobulin Y (IgY) With Broad Variant Activity as Intranasal Prophylaxis Against COVID-19.Front Immunol. 2022 Jun 1;13:899617. doi: 10.3389/fimmu.2022.899617. eCollection 2022.PMID: 35720389 Free PMC article. Clinical Trial.
References
-
- Zhou P., et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579:270–273. – PMC – PubMed
- Yan R., et al. Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. Science. 2020;367:1444–1448. – PMC – PubMed
- Brouwer P.J.M., et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. Science. 2020 – PMC – PubMed
- Cao X. COVID-19: immunopathology and its implications for therapy. Nat. Rev. Immunol. 2020;20:269–270. – PMC – PubMed
- Klemperer F. Uber natirliche Immunitat und ihre Verwertung fur die Immunisierungs-therapie. Arch. Expl. Pathol. Pharmakol. 1893;31:356–382.